---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-018106"
form_type: "8-K"
ticker: "DMAC"
cik: "0001401040"
company_name: "DiaMedica Therapeutics Inc."
filed_at: "2026-05-21T20:30:35+00:00"
generated_at: "2026-05-21T21:03:30.628647+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# DiaMedica shareholders re-elect all seven directors, approve auditor, exec compensation, and share increase

## Summary
- All seven incumbent directors re-elected; Daniel O'Connor received 5,130,879 votes withheld vs. ~200,000 for others.
- Baker Tilly US, LLP ratified as auditor for FY 2026 with 20,950,404 votes for and 578,926 against.
- Advisory vote on executive compensation approved: 9,928,381 for, 271,093 against, 149,163 abstain.
- Amendment to 2019 Omnibus Incentive Plan to increase shares by 3.5M approved: 9,693,413 for, 510,487 against.
- All proposals passed with broker non-votes of 11,180,693 on director election and other non-routine items.

## SEC filing metadata
- accession: 0001437749-26-018106
- form_type: 8-K
- ticker: DMAC
- cik: 0001401040
- company_name: DiaMedica Therapeutics Inc.
- filed_at: 2026-05-21T20:30:35+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401040/000143774926018106/0001437749-26-018106-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401040/000143774926018106/dmtp20260520_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-018106
- JSON: https://secwatch.observer/filing/0001437749-26-018106.json
- Plain text: https://secwatch.observer/filing/0001437749-26-018106.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.